Investor Relations

Investor Overview

KemPharm uses its LATTM platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.


Stock Quote
KMPH (Common Stock)
PriceChange% ChangeVolume
$3.50 - 0.12.78%91,930
Previous CloseToday's OpenIntraday HighIntraday Low
Exchange: NASDAQ (US Dollar)
07/21/17 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
KemPharm Strengthens ADHD Prodrug Pipeline with Development of KP484, A New, Super-Extended Release ADHD Methylphenidate Product Candidate
KemPharm Announces First Patent Grant for KP746, a Prodrug of Oxymorphone
KemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources